| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development (r&d) expenses, net | 6,122 | 5,014 | ||
| General and administrative expenses | 2,414 | 2,419 | ||
| Operating loss | -8,536 | -7,433 | ||
| Other expenses (income) | 24 | -70 | ||
| Interest expenses | 5 | 5 | ||
| Loss (income) from change in fair value of warrants | 730 | -1,498 | ||
| Finance expense (income), net | 84 | -25 | ||
| Loss (income) before tax | -9,163 | -6,035 | ||
| Tax expenses | 3 | 2 | ||
| Net loss (income) | -9,166 | -6,037 | ||
| Basic loss (earnings) per share of common stock (in dollars per share) | 0.29 | 0.19 | ||
| Diluted loss (earnings) per share of common stock (in dollars per share) | 0.29 | 0.19 | ||
| Weighted average number of shares used in computing basic loss (earnings) per share of common stock (in shares) | 31,399,552 | 31,308,396 | ||
| Weighted average number of shares used in computing diluted loss (earnings) per share of common stock (in shares) | 31,399,552 | 31,308,396 | ||
BiomX Inc. (PHGE)
BiomX Inc. (PHGE)